spironolactone has been researched along with Polycystic Kidney Diseases in 2 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Polycystic Kidney Diseases: Hereditary diseases that are characterized by the progressive expansion of a large number of tightly packed CYSTS within the KIDNEYS. They include diseases with autosomal dominant and autosomal recessive inheritance.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jeewandara, TM | 1 |
| Ameer, OZ | 1 |
| Boyd, R | 1 |
| Wyse, BF | 1 |
| Underwood, CF | 1 |
| Phillips, JK | 1 |
| Isdale, JM | 1 |
| Thomson, PD | 1 |
| Katz, S | 1 |
2 other studies available for spironolactone and Polycystic Kidney Diseases
| Article | Year |
|---|---|
Protective cardiorenal effects of spironolactone in a rodent model of polycystic kidney disease.
Topics: Animals; Aorta; Biomarkers; Blood Pressure; Cytoprotection; Disease Models, Animal; Disease Progress | 2015 |
Infantile polycystic disease of the kidneys.
Topics: Child, Preschool; Chlorothiazide; Female; Guanethidine; Humans; Hydralazine; Hypertension, Renal; In | 1973 |